TIDMSAR
RNS Number : 9496T
Sareum Holdings PLC
24 July 2020
(AIM: SAR)
24 July 2020
Sareum Holdings PLC
("Sareum" or the "Company")
Encouraging Preclinical Results Generated with Sareum's
TYK2/JAK1 Inhibitors in a Disease Model of Lupus
Sareum Holdings plc (AIM: SAR), the specialist drug development
company delivering targeted small molecule therapeutics to improve
the treatment of cancer and autoimmune diseases, is pleased to
announce that encouraging results have been published for its small
molecule dual tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1)
inhibitors in disease model studies of systemic lupus erythematosus
(SLE) by its collaborator, SRI International.
These studies were supported by a research grant from the US
Department of Defense (DoD) and the report was recently published
on the website of the Defense Technical Information Center
(https://apps.dtic.mil/sti/citations/AD1087498).
The authors concluded that an approach using selective TYK2/JAK1
inhibitors may lead to the development of a therapy for lupus that
does not involve the harmful side effects of systemic immune system
suppression and may benefit numerous lupus patients in need of new
options. They also noted that the results could influence
treatments of other autoimmune diseases such as arthritis and
psoriasis.
Specifically, it was reported that treatment with TYK2/JAK1
inhibitor SAR-20351 (now known as SDC-1802) reduces autoantibodies
(biological markers of lupus severity) in a spontaneous mouse model
of SLE. The data also provided evidence that SAR-20351 inhibits
cytokines that play a critical role in lupus, including
interferon-alpha, IL-6 and IL-23. The inhibition of IL-23
signalling by SAR-20351 may play a role in the decrease of
autoantibodies in the lupus mouse model, as IL-23 signalling drives
the differentiation of Th17 cells, which leads to autoantibody
production and are pathogenic in lupus.
SAR-20351/SDC-1802 has been selected as a preclinical
development candidate targeting cancer based on its overall profile
that includes supportive data recently presented in October 2019 at
the AACR-NCI-EORTC International Cancer Conference. Sareum is
advancing a different TYK2/JAK1 inhibitor - SDC-1801 - as a
preclinical candidate targeting autoimmune diseases.
Dr Tim Mitchell, CEO of Sareum, commented :
"These data from studies using our small molecule TYK2/JAK1
inhibitors add to the body of evidence supporting this novel
mechanism of action as a promising approach to treating autoimmune
diseases such as SLE. Our own studies have also confirmed this
potential in autoimmune diseases such as psoriasis and rheumatoid
arthritis and we are delighted that this work indicates a possible
application in lupus, which remains a condition with high unmet
medical need. This approach has also been recognised more broadly
in the industry with several molecules targeting this pathway
advancing through development. We look forward to reporting further
progress as we advance our TYK2/JAK1 candidates through preclinical
development."
Sareum entered into a co-development agreement with SRI
International (Menlo Park, CA, USA) in April 2013 to develop TYK2
inhibitors in autoimmune diseases. Sareum retains commercialisation
rights for these and other TYK2 inhibitors with profiles optimised
for oncology indications.
About Lupus
Lupus is an autoimmune disease in which the body's immune system
attacks healthy tissue in many parts of the body. Common symptoms
include painful and swollen joints, fever, chest pain, hair loss,
mouth ulcers, swollen lymph nodes, feeling tired and a red rash,
which is most commonly on the face. Lupus significantly increases
the risk of cardiovascular disease with this being the most common
cause of death. The Lupus Foundation of America estimates that at
least five million people worldwide have a form of lupus, with
systemic lupus erythematosus (SLE) accounting for 70% of all cases.
The rate of SLE in developed countries ranges from 20 to 70 per
100,000. Women between the ages of 15 and 45 are affected about
nine times more often than men.*
* Sources - The Lupus Foundation of America, Wikipedia
The information contained within this announcement is deemed by
the Company to constitute inside information under the Market Abuse
Regulation (EU) No. 596/2014
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Financial PR)
Mark Swallow/ David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the "cytokine storm" immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802). The Company is targeting completion of
preclinical development for each molecule in 2020.
The Company's preclinical FLT3+Aurora inhibitor programme
targeting haematological cancers is licensed to a China-based
specialty pharma company.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in
genetically defined patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc., which
is currently seeking to on-license SRA737 to a third party for
further development.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com.
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESFLFSADAIVFII
(END) Dow Jones Newswires
July 24, 2020 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024